Loading stock data…
Privia Health Group (PRVA)
$25.55-0.02 (-0.08%)
Market ClosedLast close Jun 29
Privia Health Group, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Privia Health Group, Inc. in the Healthcare sector is trading at $25.55 with a market capitalization of $3.0B. Wall Street consensus targets $31.42 (19 analysts), implying a +23.0% move over the next 12 months. The stock is currently near its 52-week high of $26.51, remaining 9.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $603.85M↑ | $541.17M↓ | $580.42M↑ | $521.15M↑ | $480.10M |
| Gross Profit | $60.31M↑ | $49.66M↓ | $63.77M↑ | $50.24M↑ | $45.76M |
| Operating Income | $7.42M↓ | $11.28M↓ | $14.40M↑ | $3.34M↓ | $5.22M |
| Net Income | $3.06M↓ | $9.15M↑ | $6.86M↑ | $2.69M↓ | $4.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.89%
Volume
Today's trading volume
1.20M
Recent News
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Stocks Under $50 That Fall Short
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Privia's CEO Just Sold 121,000 Shares for $2.7 Million
This healthcare technology firm supporting independent physicians reported a notable insider sale.
How The Privia Health Group (PRVA) Narrative Is Shifting With Mixed Targets And New Deals
Privia Health Group’s fair value estimate has been trimmed slightly from US$31.80 to US$31.60, a modest 0.6% reduction in the latest analyst model update. That adjustment lines up with mixed Street commentary, where some firms have lifted targets toward US$35 while others have moved down to around US$24 as they weigh company execution against sector risks. As you read on, you will see how these shifting targets feed into the evolving narrative around Privia Health’s stock. Wall Street's...
Q1 Rundown: Privia Health (NASDAQ:PRVA) Vs Other Healthcare Technology for Providers Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at healthcare technology for providers stocks, starting with Privia Health (NASDAQ:PRVA).